Welcome to our dedicated page for Baudax Bio news (Ticker: BXRX), a resource for investors and traders seeking the latest updates and insights on Baudax Bio stock.
Baudax Bio, Inc. (NASDAQ: BXRX) is a specialized pharmaceutical company focused on developing and commercializing innovative products designed to meet the needs of hospital and acute care settings. The company's lead product candidate is an intravenous form of meloxicam, a non-opioid analgesic that has completed Phase III clinical trials for the management of moderate to severe pain. Current research includes Phase IIIB clinical trials aiming to assess opioid consumption, pain intensity, and the length of hospital stay in colorectal and orthopedic surgery patients. These trials also evaluate various pharmacoeconomic parameters.
Beyond meloxicam, Baudax Bio is advancing a pipeline of early-stage product candidates including RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) in Phase I clinical trials, and RP2000, an ultra-short-acting NMBA currently in pre-clinical trials. The company is also developing a reversal agent for these NMBAs and DEX-IN, a proprietary intranasal formulation of dexmedetomidine.
Recently, Baudax Bio announced that the U.S. FDA has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is a next-generation Treg therapy designed to address Hemophilia A patients with FVIII inhibitors effectively.
Founded in 2019 and based in Malvern, Pennsylvania, Baudax Bio continues to push forward with its mission to develop meaningful therapeutic solutions for acute care settings, drawing on robust clinical research and innovative therapeutic approaches.
On March 3, 2022, Baudax Bio (NASDAQ:BXRX) announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This compliance was determined after the company's stock closed above $1.00 for 10 consecutive business days from February 16 to March 2, 2022. The matter is now considered closed by Nasdaq. Baudax Bio focuses on innovative products for acute care, with its lead product, ANJESO, being the first and only 24-hour IV COX-2 preferential NSAID for managing moderate to severe pain.
Baudax Bio, Inc. (NASDAQ:BXRX) announced the issuance of United States Patent No. 11,253,478 for its product ANJESO, covering new injectable meloxicam compositions. This patent, expiring in May 2030, reinforces exclusivity for ANJESO, which now has a total of six patents listed in the FDA's Orange Book. The patent aims to create a barrier against generic competitors. ANJESO is indicated for managing moderate to severe pain without the risks associated with opioids, backed by extensive clinical trials.
Baudax Bio (NASDAQ: BXRX) announced the pricing of a public offering of 3,508,772 shares of common stock, alongside warrants for the same amount. The offering is priced at $2.85 per share, with an expected gross proceeds of approximately $10 million before expenses. The warrants have an exercise price of $3.25 and will expire in five years. The funds are intended for the commercialization of ANJESO, pipeline development, and general corporate purposes. The offering is set to close around March 1, 2022, subject to customary conditions.
Baudax Bio (NASDAQ: BXRX) has initiated a proposed underwritten public offering of its common stock and warrants. The offering is intended to raise funds for the commercialization of ANJESO, pipeline development, and general corporate purposes. The offering is subject to market conditions, and a preliminary prospectus has been filed with the SEC. H.C. Wainwright & Co. is acting as the sole book-running manager. The company emphasizes that there is no assurance of completion or specific terms of the offering.
Baudax Bio (NASDAQ:BXRX) announced a 1-for-35 reverse stock split, effective February 16, 2022, to comply with Nasdaq's $1.00 minimum bid price requirement. The split reduces outstanding shares from approximately 101.6 million to about 2.9 million, maintaining par value at $0.01 per share. Shareholders will receive cash for any fractional shares. This move aims to enhance the stock's market price and attract new investors, with adjustments made to outstanding stock options and warrants.
MALVERN, Pa., Jan. 4, 2022 - Baudax Bio (NASDAQ:BXRX) announced that CEO Gerri Henwood will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation will be available for on-demand listening starting January 10, 2022, at 7:00 a.m. ET on the company's website, with a replay available for 30 days afterward.
Baudax Bio specializes in developing innovative products for acute care, including ANJESO, a unique 24-hour intravenous NSAID for managing moderate to severe pain, alongside a promising pipeline of neuromuscular blocking agents.
Baudax Bio (NASDAQ:BXRX) announced on December 31, 2021, that its Compensation Committee approved stock option grants totaling 109,250 shares and restricted stock units covering 31,900 shares to 14 newly-hired employees. These grants, effective December 29, 2021, are compliant with Nasdaq Rule 5635(c)(4), serving as inducements for employment. The options will have an exercise price of $0.22 per share, vesting over four years. Baudax Bio focuses on acute care products and is known for ANJESO, the first IV COX-2 preferential NSAID for pain management.
Baudax Bio (NASDAQ:BXRX) has announced a definitive agreement to sell 42,289.3 shares of convertible preferred stock and warrants for gross proceeds of $4.2 million. The preferred stock, convertible into 16,915,720 shares of common stock at $0.25 each, and warrants at $0.32, aim to support the commercialization of ANJESO and other pipeline activities. The transaction, expected to close on December 28, 2021, involves the establishment of voting rights, enabling preferred stockholders to influence decisions on a proposed reverse stock split.
MALVERN, Pa., Nov. 15, 2021 - Baudax Bio, a pharmaceutical company focused on developing innovative acute care products, announced that its CEO Gerri Henwood will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The chat will be available for on-demand listening starting November 22, 2021, at 10:00 a.m. ET on the company's website. Baudax Bio's lead product, ANJESO, is the first 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain.
Baudax Bio (NASDAQ:BXRX) announced the completion of a dose-escalation study for BX-1000, an intermediate-duration neuromuscular blocking agent (NMB), which was generally well tolerated. The study involved 58 healthy volunteers and monitored rapid muscle paralysis and subsequent recovery. The company is preparing to submit a clinical study report to the FDA and plans to advance BX-2000 and BX-3000 into clinical studies in 2022, after completing toxicology studies. These NMBs can reduce recovery times in surgical settings, promising significant cost savings for healthcare facilities.
FAQ
What is the market cap of Baudax Bio (BXRX)?
What is the primary focus of Baudax Bio, Inc.?
What is Baudax Bio's lead product candidate?
What other products are in Baudax Bio's pipeline?
What recent regulatory milestone has Baudax Bio achieved?
Where is Baudax Bio headquartered?
When was Baudax Bio incorporated?
What is the status of meloxicam's clinical trials?
What is TI-168?
Who can I contact for investor relations information?
Are there any other clinical trials Baudax Bio is involved in?
